Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02900651
Title Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

nasopharynx carcinoma

sarcoma

prostate cancer

Advanced Solid Tumor

diffuse large B-cell lymphoma

ovarian clear cell carcinoma

stomach cancer

Therapies

MAK683

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN


No variant requirements are available.